Category: Imaging & mpMRI
No, the title does not refer to sex, a Ferrari, a promotion, or winning the lottery. It’s a quote from Dr. Robert Nam from Toronto’s Sunnybrook Health Sciences Centre about the number of applicants for a clinical study of using 3T MRI to screen for prostate cancer (PCa).[i] There were 50 openings, but 300 applicants. keep reading
Testosterone has important benefits for men. When it’s at a normal level, it helps develop muscle mass, decrease fat, avoid depression, keep bones strong, maintain libido, improve erections, and may help reduce risks of cardiovascular and cognitive disease. However, about 40% of men over the age of 45 have symptoms of reduced blood levels of keep reading
It’s time to silence the economic naysayers who claim that multiparametric MRI (mpMRI) is too expensive for detecting and diagnosing prostate cancer. Results from a new study out of Brigham and Women’s Hospital[i] (Boston, MA) in partnership with AdMeTech reflect how the Sperling Prostate Center has been ahead of its time. The study demonstrates how keep reading
Androgen deprivation therapy (ADT) is a treatment for prostate cancer that has spread outside the gland. It is also called hormone therapy or chemical castration. The purpose of ADT is to reduce the production of male hormones, especially testosterone, which has the effect of temporarily halting the ability of prostate cancer cells to multiply and keep reading
Dr. Peter Pinto is one of the most respected urologic researchers in America. He is the Head of the Prostate Cancer Section of the Urologic Oncology Branch of the Center for Cancer Research (National Cancer Institute/National Institutes of Health). That’s a very long formal title for a man who is humble, personable and good-natured. His keep reading
When an authoritative person weighs in on a topic, we sit up and take notice. Dr. Ardeshir (Art) Rastinehead is an Interventional Urologic Oncologist and he is impressively credentialed. His experience includes fellowship training at the National Cancer Institute (NIH) with. Peter A. Pinto and Bradford J. Wood, pioneers in the research and development of keep reading
When an authoritative person weighs in on a topic, we sit up and take notice. Dr. Ardeshir (Art) Rastinehead is an Interventional Urologic Oncologist and he is impressively credentialed. His experience includes fellowship training at the National Cancer Institute (NIH) with. Peter A. Pinto and Bradford J. Wood, pioneers in the research and development of keep reading
It is always gratifying for a doctor when something he or she wholeheartedly believes in gets affirmed by published research. For me, this is the case with a new Italian study, “The Roles of Multiparametric MRI, PCA3, and PHI: Which Is The Best Predictor of Prostate Cancer After a Negative Biopsy?”[i] The authors recognize the keep reading
I’m excited to announce news about a new way to quantify the effects of focal laser ablation (FLA) in a way that may allow us to predict long term treatment success. I was a member of a research team out of Case Western Reserve University that developed an innovative way to use MRI before, during keep reading
A prominent urologist wrote an articulate article on how the U.S. Preventive Services Task Force made a recommendation against broad PSA screening based on an oversimplification of a complex issue. He made an eloquent declaration on several ways in which urologists are “embracing strategies to preserve, or even further decrease, prostate cancer mortality while minimizing keep reading
